1500억 '바이오 3상 펀드' 등판…현실 외면한 정책에 회의론 커져 [넘버스]

This policy move highlights a significant disconnect between government-led financial support and the 'License-out' business reality of the domestic bio-industry, where most firms lack the infrastructure for late-stage development. It signals a critical need for policy frameworks to align with actual R&D lifecycles rather than pushing for high-risk Phase 3 completion that exceeds current local capacity.